Laminar_CL-0059_LAMINAR LAAX

What is the Purpose of this Study?

The purpose of this study is to compare the safety and efficacy of the Laminar System (Investigational device) to commercially available left atrial appendage closure (LAAC) devices, such as Watchman FLX and Amulet (Control devices) in patients with non-valvular atrial fibrillation (NVAF) who are deemed appropriate for LAAC to reduce the risk of stroke and systemic embolism.

Eligibility

1. Documented NVAF, defined as AF (paroxysmal, persistent, or permanent) in the absence of moderate-to-severe mitral stenosis or a mechanical heart valve.
2. Subject ≥18 years old.
3. CHA2DS2-VASc score ≥ 2 in men and ≥ 3 in women.
4. Subject deemed appropriate for LAA closure by the Site Investigator and a clinician not a part of the procedural team using an evidenced based decision-making tool.

Inclusion Criteria:

1. Documented NVAF, defined as AF (paroxysmal, persistent, or permanent) in the absence of moderate-to-severe mitral stenosis or a mechanical heart valve.
2. Subject ≥18 years old.
3. CHA2DS2-VASc score ≥ 2 in men and ≥ 3 in women.
4. Subject deemed appropriate for LAA closure by the Site Investigator and a clinician not a part of the procedural team using an evidenced based decision-making tool.
5. Subject is recommended for chronic oral anticoagulation therapy (OAC) but has an appropriate rationale to seek a non-pharmacologic alternative.
6. Subject eligible for the protocol-specified post-procedural antithrombotic regimen.
7. Subject or Legally Authorized Representative informed of the nature of the study, is willing and able to comply with the protocol, and has provided written informed consent per Institutional Review Board (IRB) requirements.

Exclusion Criteria:

Medical History
1. Single episode, transient, or reversible AF (e.g., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures).
2. Stroke or transient ischemic attack within 90 days before the index procedure.
3. Myocardial infarction or unstable angina within 90 days before the index procedure.
4. Prior cardiac surgery or surgery requiring sternotomy
5. Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2 or patients with end stage renal disease who are dialysis dependent.
6. Active infection undergoing treatment.
7. History of symptomatic pericarditis (acute or chronic).
Coexisting Cardiovascular Disease
8. Cardiac tumor.
9. History of mitral valve or other severe cardiac valvular disease requiring intervention or presence of prosthetic mechanical valve.
10. Medical condition (other than AF) that mandates chronic oral anticoagulation (e.g., history of unprovoked deep vein thrombosis or pulmonary embolism, or mechanical heart valve).
11. Severe heart failure (New York Heart Association Class IV).
12. Symptomatic carotid artery disease (\>50% diameter reduction with prior ipsilateral stroke or TIA) or established asymptomatic carotid artery disease (diameter reduction of \>70%).
Previous or Planned Interventions
13. Previous left atrial ablation procedure in the 90 days before the index procedure date or planned left atrial ablation to be performed in less than 90 days after the index procedure.
14. Recent (within 30 days before the index procedure) or planned (within 60 days after the index procedure) cardiac interventional procedures (e.g., percutaneous coronary intervention, structural heart valve procedures, or other electrophysiologic ablation procedure, etc.)
15. Planned (within 60 days after the index procedure) cardiac surgical procedures or any surgeries which require sternotomy.
16. Recent (within 30 days before the index procedure) or planned (within 60 days after the index procedure) noncardiac procedures or surgical interventions.
17. Intracardiac thrombus or persistent dense spontaneous echo contrast visualized by screening TEE or by TEE performed at time of index procedure.
18. Left ventricular ejection fraction (LVEF) \<30%.
19. Circumferential pericardial effusion \>10 mm, symptomatic pericardial effusion, evidence of tamponade physiology.
20. Complex atheroma with mobile plaque of the aorta.
Procedural contraindications
21. Pre-procedural interatrial communication, atrial septal defect, or patent foramen ovale that warrants closure.
22. Transfemoral vascular access precluding delivery of implant with catheter-based system.
23. Presence of inferior vena cava (IVC) filter that would interfere with access.
24. Subject unable to undergo general anesthesia.
25. Subject with condition which precludes adequate transesophageal echocardiographic (TEE) assessment.
Contraindications to Required Medications
26. Known allergy, hypersensitivity or contraindication to aspirin, heparin, or device materials (e.g., nickel, titanium \[i.e. nitinol\]).
27. Contrast sensitivity that cannot be adequately pre-medicated.
28. Bleeding diathesis or coagulopathy.
29. Persistent thrombocytopenia (platelet count \<75,000 cells/mm3), thrombocytosis (\>700,000 cells/mm3), or leukopenia (white blood cell count \<3,000 cells/mm3).
General Exclusions
30. Left atrial appendage anatomy which cannot accommodate both commercially available control device and the Laminar Implant per manufacturer IFU.
31. Pregnant or nursing and those who plan pregnancy in the period up to 1 year following the index procedure. Subjects of childbearing potential must have a negative pregnancy test (per site standard test) within 7 days before index procedure.
32. Known other medical illness or known history of substance abuse that may cause non-compliance with the protocol or protocol-specified medication regimen, confound the data interpretation, or is associated with a life expectancy of less than 1 year.
33. Current participation in another investigational drug or device study that in the opinion of the investigator could confound the data interpretation.

Show less

Where can I participate?

Beverly

More about this Clinical Trial

What is the full name of this clinical trial?

Laminar Left Atrial Appendage Elimination Pivotal IDE Study

Study Details

Disease Type/Condition

Other

Principal Investigator

Makkar, Rajendra

Age Group

Adult

Phase

III

IRB Number

STUDY00003733

ClinicalTrials.gov ID

NCT06168942

Key Eligibility

ClinicalTrials.gov

How do I learn more about this study?

clinicaltrials@cshs.org